Palvella Therapeutics to Advance QTORIN Pitavastatin into Phase 2 Trials for Porokeratosis
I'm PortAI, I can summarize articles.
Palvella Therapeutics Inc. announced plans to advance QTORIN™ pitavastatin into Phase 2 trials for disseminated superficial actinic porokeratosis (DSAP) in the second half of 2026. This follows a systematic review published in Clinical and Experimental Dermatology, which highlights treatment gaps due to the absence of FDA-approved therapies for porokeratosis. The review synthesizes evidence from 24 studies but does not present new clinical results. Future trials are planned to further investigate this treatment.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments